



DURACLONE IM

ACCELERATE YOUR PACE IN CLINICAL RESEARCH



Powered By

DURA Innovations

Dry Unitized Reagent Assays

VISUALIZE
the possibilities.

For Research Use Only. Not for use in diagnostic procedures

 **BECKMAN
COULTER**
Life Sciences

ACCELERATE YOUR PACE IN CLINICAL RESEARCH

Antibody panel development requires a high level of flow cytometry expertise and may consume critical laboratory resources. Take a leap forward and streamline panel implementation in your laboratory by using expert proven, dry DURAClone IM antibody combinations - the ideal solution for longitudinal and multi-center clinical research studies!

- Dry format, unitized for a single test - no antibody pipetting
- Adaptable to your research by addition of liquid reagents
- Compensation solution included (where required)
- Expert-proven and thoroughly tested
- GMP*-compliant manufacturing
- Simplified inventory management

* While this product is intended for Research Use Only (RUO), it has been manufactured with process controls consistent with relevant Good Manufacturing Practices (GMP).

DURAClone IM

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Phenotyping Basic Tube - B53309	25 tests - RUO	-	CD45	CD16	CD56	CD19	-	CD14	CD4	-	CD8	-	CD3
NEW IM Phenotyping Basic Plate - C97741	192 tests - RUO												
IM B Cell Tube - B53318	25 tests - RUO	IgM	CD45	IgD	CD21	CD19	-	CD27	CD24	-	-	-	CD38
IM T Cell Subsets Tube - B53328	25 tests - RUO	CD57	CD45	CD45RA	CCR7	CD28	CD279 (PD-1)	CD27	CD4	-	CD8	-	CD3
IM TCRs Tube - B53340	25 tests - RUO	TCRV δ 2	CD45	TCR γ δ	TCR $\alpha\beta$	HLA-DR	-	TCRV δ 1	CD4	-	CD8	-	CD3
IM Treg Tube - B53346	25 tests - RUO	Helios	CD45	CD45RA	CD25	-	CD39	CD4	-	FoxP3	-	-	CD3
IM Dendritic Cells Tube - B53351	25 tests - RUO	HLA-DR	CD45	CD16	Lineage ¹	-	CD1c	CD11c	CD370 (Clec9A)	-	-	CD123	-
IM Granulocytes Tube - B88651	25 tests - RUO	CD15	CD45	CD294 (CRTH2)	-	CD16	CD33	CD11b	CD274 (PD-L1)	-	-	Lineage ²	CD62L
IM Count Tube - C00162	25 tests - RUO	-	-	CD45	Counting Beads	-	7-AAD	-	-	-	-	-	-
IM Innate Lymphoid Cells tube - C96081	25 tests - RUO	-	CD45	CD294 (CRTH2)	Lineage ³	-	CD117	CD335 (Nkp46)	CD127	-	-	-	CD161

¹ CD3 / CD14 / CD19 / CD20 / CD56

² CD3 / CD14 / CD19 / CD56

³ CD1a / CD3 / CD14 / CD16 / CD19 / CD34 / CD94 / CD123 / TCR $\alpha\beta$ / TCR γ δ / Fc ϵ R1a


SIMPLIFY YOUR REAGENT INVENTORY MANAGEMENT...

Working with cocktails prepared from liquid antibodies is associated with complex and time consuming inventory management impacting laboratory productivity. DURAClone IM kits simplify inventory management dramatically by replacing multiple different single color reagents with just 1 pre-formulated product.



Reagent Inventory Management	Liquid Cocktails from Single Color Reagents	DURAClone IM
QC of reagent lots	Multiple single color reagent lots for each panel	1 reagent lot for each panel
Format	- Liquid - Mix from single color reagents with varying test volumes and staggered expiry dates	- Dry - Unitized per test
Reagent waste sources	- Pipetting failure - Unused remnant volume - Non-stoichiometric consumption of single color reagents	None
Storage / Shipping conditions	Refrigerated	Room temperature

...AND YOUR CYTOMETRY WORKFLOW*



* Please note deviating workflows for IM Treg (B53346, intracellular staining), IM B Cell (B53328, pre-washing step), IM Phenotyping BASIC Plate and IM Count (C97741, C00162 no final wash step). Please refer to respective instructions for use (IFU) for detailed protocols (www.beckman.com).

DATA EXAMPLES

The following data examples have been acquired on a CytoFLEX 13 color instrument, not using the detector set to its full capacity. Please consider the shown examples also as a possible robust framework allowing you to add further antibodies to adapt the panels to your specific research needs. *

* Compatibility of the DURAClone IM kits must be verified by the user for each reagent added. Performance characteristics may vary depending on the type of instrument.

DURAClone IM Phenotyping Basic

Tube (whole blood)





Plate (PBMCs, no wash; also compatible with whole blood)




Identification of principal lymphocyte subsets as well as subpopulations of monocytes.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Phenotyping Basic Tube - B53309	25 tests - RUO	-	CD45	CD16	CD56	CD19	-	CD14	CD4	-	CD8	-	CD3
NEW IM Phenotyping Basic Plate - C97741	192 tests - RUO												

Analyzed with  Kaluza data analysis software

DATA EXAMPLES


DURAClone IM Count



Absolute counting/viability for whole blood samples and counting reference for all DURAClone IM panels.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Count Tube - C00162	25 tests - RUO	-	-	CD45	Counting Beads		7-AAD	-	-	-	-	-	-

DURAClone IM B Cell




Delineation of B cell maturation, including transitional stage, isotype class switch, naïve and memory stages.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM B Cell Tube - B53318	25 tests - RUO	IgM	CD45	IgD	CD21	CD19	-	CD27	CD24	-	-	-	CD38

Analyzed with  Kaluza data analysis software

DATA EXAMPLES


DURAClone IM T Cell Subsets



Delineation of B cell maturation, including transitional stage, isotype class switch, naïve and memory stages.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM T Cell Subsets Tube - B53328	25 tests - RUO	CD57	CD45	CD45RA	CCR7	CD28	CD279 (PD-1)	CD27	CD4	-	CD8	-	CD3

DURAClone IM TCRs




Assessment of TCR $\alpha\beta$ and $\gamma\delta$ chain expression and detection of V δ 1+ and V δ 2+ subsets among TCR $\gamma\delta$ + T cells.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM TCRs Tube - B53340	25 tests - RUO	TCRV δ 2	CD45	TCR $\gamma\delta$	TCR $\alpha\beta$	HLA-DR	-	TCRV δ 1	CD4	-	CD8	-	CD3

Analyzed with  Kaluza data analysis software

DATA EXAMPLES


DURAClone IM Treg



Identification and characterization of FoxP3⁺ regulatory T cells using a streamlined permeabilization protocol.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Treg Tube - B53346	25 tests - RUO	Helios	CD45	CD45RA	CD25	-	CD39	CD4	-	FoxP3	-	-	CD3

DURAClone IM Dendritic Cells




Identification of plasmacytoid dendritic cells and 3 major subsets of myeloid dendritic cells.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Dendritic Cells Tube - B53351	25 tests - RUO	HLA-DR	CD45	CD16	Lineage ¹	-	CD1c	CD11c	CD370 (Clec9A)	-	-	CD123	-

Analyzed with  Kaluza data analysis software

DATA EXAMPLES


DURAClone IM Granulocytes



Identification of Basophils, Eosinophils and Neutrophils including assessment of CD16 and CD11b as well as activation-dependent CD62L and PD-L1 co-expression.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Granulocytes Tube - B88651	25 tests - RUO	CD15	CD45	CD294 (CRTH2)	-	CD16	CD33	CD11b	CD274 (PD-L1)	-	-	Lineage ²	CD62L

DURAClone IM Innate Lymphoid Cells



Assessment of TCR $\alpha\beta$ and $\gamma\delta$ chain expression and detection of V δ 1+ and V δ 2+ subsets among TCR $\gamma\delta$ + T cells.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm				
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF700	APC-AF750
IM Innate Lymphoid Cells tube - C96081	25 tests - RUO	-	CD45	CD294 (CRTH2)	Lineage ³	-	CD117	CD335 (NKp46)	CD127	-	-	-	CD161

Analyzed with  Kaluza data analysis software

SELECTED RESEARCH PUBLICATIONS

DURAClone IM in infection and immunity

Hutchinson JA, Weigand K, Adenugba A, Kronenberg K, Haarer J, Zeman F, Riquelme P, Hornung M, Ahrens N, Schlitt HJ, Geissler EK, Werner JM. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers. *Front Immunol*. 2018 Feb 7;9:146.

Di Sante G, Buonsenso D, De Rose C, Tredicine M, Palucci I, De Maio F, Camponeschi C, Bonadia N, Biasucci D, Pata D, Chiaretti A, Valentini P, Ria F, Sanguinetti M, Sali M. Immunopathology of SARS-CoV-2 Infection: A Focus on T Regulatory and B Cell Responses in Children Compared with Adults. *Front Immunol*. 2022 May 7;9(5):681.

Agrati C, Cossarizza A, Mazzotta V, et al. Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study. *Lancet Infect Dis*. 2023 Mar;23(3):320-330.

Lo Tartaro D, Camiro-Zúñiga A, Nasi M, et al. Effective Treatment of Patients Experiencing Primary, Acute HIV Infection Decreases Exhausted/Activated CD4+ T Cells and CD8+ T Memory Stem Cells. *Cells*. 2022 Jul 27;11(15):2307.

Lo Tartaro D, Paolini A, Mattioli M, Swatler J, Neroni A, Borella R, Santacroce E, Di Nella A, Gozzi L, Busani S, Cuccorese M, Trenti T, Meschiari M, Guaraldi G, Girardis M, Mussini C, Piwocka K, Gibellini L, Cossarizza A, De Biasi S. Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination. *Front Immunol*. 2023 Feb 9;14:1123724.

Maamari KA, Busaidi IA, Kindi MA, Zadjali F, BaAlawi F, Anesta W, Amri KA, Albalushi W, Balushi HA, Amri AA, Aljufaili M, Al-Busaidi M, Muharrmi ZA, Balkhair A, Riyami NA, Ghanim Z, Alshekaili J. Short and long-term immune changes in different severity groups of COVID-19 disease. *Int J Infect Dis*. 2022 Sep;122:776-784.

Mohanraj D, Baldwin S, Singh S, Gordon A, Whitelegg A. Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients. *Cell Immunol*. 2022 Mar;373:104501.

De Biasi S, Mattioli M, Meschiari M, Lo Tartaro D, Paolini A, Borella R, Neroni A, Fidanza L, Busani S, Girardis M, Coppi F, Mattioli AV, Guaraldi G, Mussini C, Cossarizza A, Gibellini L. Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab. *Front Immunol*. 2023 May 5;14:1123807.

Romano A, Parrinello NL, Barchitta M, et al. In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection. *Sci Rep*. 2022 May 4;12(1):7237.

De Biasi S, Lo Tartaro D, Meschiari M, et al. Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia. *Eur J Immunol*. 2020 Sep;50(9):1283-1294.

DURAClone IM in immune oncology

Peuker CA, Yaghoobramzi S, Grunert C, et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. *Eur J Cancer*. 2022 Feb;162:45-55.

Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. *Thyroid*. 2020 Oct;30(10):1440-1450.

Holl EK, Frazier VN, Landa K, Beasley GM, Hwang ES, Nair SK. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. *Front Immunol*. 2019 Jul 31;10:1767.

Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, Pohl A, Miloud T, Burgaud M, Vucinic V, Platzbecker U, Sack U, Fricke S, Koehl U. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. *Front Immunol*. 2021 May 3;12:658314.

Gaynor N, Blanco A, Madden SF, et al. Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy. *Br J Cancer*. 2023 Oct;129(6):1022-1031.

Chi P, Jiang H, Li D, Li J, Wen X, Ding Q, Chen L, Zhang X, Huang J, Ding Y. An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets. *Front Immunol*. 2022 Dec 7;13:1012673.

Hutchinson JA, Kronenberg K, Riquelme P, et al. Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. *Nat Commun*. 2021 Mar 4;12(1):1439.

Coppola L, Saldone G, D'aiuto M, D'aiuto G, Mossetti G, Rinaldo M, Verticilo S, Nicolai E, Salvatore M, Mirabelli P. Identification of Immune Cell Components in Breast Tissues by a Multiparametric Flow Cytometry Approach. *Cancers (Basel)*. 2022 Aug 10;14(16):3869.

Decker AS, Pylaeva E, Brenzel A, Spyra I, Droege F, Hussain T, Lang S, Jablonska J. Prognostic Role of Blood NETosis in the Progression of Head and Neck Cancer. *Cells*. 2019 Aug 21;8(9):946.

Beasley GM, Brown MC, Farrow NE, et al. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. *J Immunother Cancer*. 2022 Sep;10(9):e005052.

Eckhoff AM, Brown MC, Landa K, Naqvi I, Holl EK, Boczkowski D, Fletcher A, Rhodin KE, Giang MH, Sullenger B, Beasley GM, Allen PJ, Nair SK. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms. *Front Immunol*. 2023 Jul 28;14:1116034.

Sagnella SM, Yang L, Stubbs GE, Boslem E, Martino-Echarri E, Smolarczyk K, Pattison SL, Vanegas N, St Clair E, Clarke S, Boockvar J, MacDiarmid JA, Brahmabhatt H. Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. *Cancer Cell*. 2020 Mar 16;37(3):354-370.e7.

SELECTED RESEARCH PUBLICATIONS

DURAClone IM in autoimmunity and tolerance

Muckenhuber M, Mucha J, Mengrelis K, How C, Reindl-S. R, Heinzel A, Kainz V, Worel N, Berlakovich G, Edinger M, Oberbauer R, Wekerle T. Optimum timing of antithymocyte globulin in relation to adoptive regulatory T cell therapy. *Am J Transplant.* 2023 Jan;23(1):84-92.

Lui SW, Hsieh TY, Lu JW, Chen YC, Lin TC, Ho YJ, Liu FC. Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets. *APMIS.* 2023 Sep;131(9):498-509.

D'Amico E, Zanghi A, Parrinello NL, Romano A, Palumbo GA, Chisari CG, Toscano S, Raimondo FD, Zappia M, Patti F. Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis. *Front Immunol.* 2022 Feb 22;13:819136.

Čelakovská J, Čermáková E, Boudkova P, Krejsek J. Evaluation of innate lymphoid cells and their subsets in atopic dermatitis patients with and without dupilumab therapy. *J Dermatolog Treat.* 2024 Dec;35(1):2299721.

Wei Y, Chen X, Zhang H, Su Q, et al. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study. *Front Immunol.* 2021 Jun 25;12:662441.

Kroemer A, Belyayev L, Khan K, et al. Rejection of intestinal allotransplants is driven by memory T helper type 17 immunity and responds to infliximab. *Am J Transplant.* 2021 Mar;21(3):1238-1254.

Bakhtiar S, Kaffenberger C, Salzmann-Manrique E, Donhauser S, Lueck L, Karaca NE, Gonzalez-Granado LI, Hazar E, Keles S, Seidel MG, Fekadu J, Königs C, Schubert R, Bader P, Huenecke S. Regulatory B cells in patients suffering from inborn errors of immunity with severe immune dysregulation. *J Autoimmun.* 2022 Oct;132:102891.

Landwehr-Kenzel S, Müller-Jensen L, Kuehl JS, et al. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. *Mol Ther.* 2022 Jun 1;30(6):2298-2314.

DURAClone IM in regeneration

Niemann M, Ort M, Lauterbach L, et al. Individual immune cell and cytokine profiles determine platelet-rich plasma composition. *Arthritis Res Ther.* 2023 Jan 10;25(1):6.

Schlundt C, Reinke S, Geissler S, Bucher CH, Giannini C, Märdian S, Dahne M, Kleber C, Samans B, Baron U, Duda GN, Volk HD, Schmidt-Bleek K. Individual Effector/Regulator T Cell Ratios Impact Bone Regeneration. *Front Immunol.* 2019 Aug 16;10:1954.

Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, Kieffer TJ. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. *Cell Stem Cell.* 2021 Dec 2;28(12):2047-2061.e5.

DURAClone IM in humanized mouse models

Bruss C, Kellner K, Ortmann O, Seitz S, Brockhoff G, Hutchinson JA, Wege AK. Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice. *Cancers (Basel).* 2022 Apr 28;14(9):2214.

Sawada J, Perrot CY, Chen L, Fournier-Goss AE, Oyer J, Copik A, Komatsu M. High Endothelial Venules Accelerate Naive T Cell Recruitment by Tumor Necrosis Factor-Mediated R-Ras Upregulation. *Am J Pathol.* 2021 Feb;191(2):396-414.

Lamb LS, Pereboeva L, Youngblood S, Gillespie GY, Nabors LB, Markert JM, Dasgupta A, Langford C, Spencer HT. A combined treatment regimen of MGMT-modified $\gamma\delta$ T cells and temozolomide chemotherapy is effective against primary high grade gliomas. *Sci Rep.* 2021 Oct 26;11(1):21133.

DURAClone IM in physical stress and aging

Stervbo U, Roch T, Kornprobst T, et al. Gravitational stress during parabolic flights reduces the number of circulating innate and adaptive leukocyte subsets in human blood. *PLoS One.* 2018 Nov 14;13(11):e0206272.

Ciocca M, Zaffina S, Fernandez Salinas A, Bocci C, Palomba P, Conti MG, Terreri S, Frisullo G, Giorda E, Scarsella M, Brugaletta R, Vinci MR, Magnavita N, Carsetti R, Piano Mortari E. Evolution of Human Memory B Cells From Childhood to Old Age. *Front Immunol.* 2021 Jul 23;12:690534.

Nasi M, Bianchini E, Lo Tartaro D, et al. Effects of whole-body cryotherapy on the innate and adaptive immune response in cyclists and runners. *Immunol Res.* 2020 Dec;68(6):422-435.

DURAClone IM in protocols and methods

Braudeau C, Salabert-Le Guen N, Chevreuil J, Rimbert M, Martin JC, Josien R. An easy and reliable whole blood freezing method for flow cytometry immuno-phenotyping and functional analyses. *Cytometry B Clin Cytom.* 2021 Nov;100(6):652-665.

Cossarizza A, Chang HD, Radbruch A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). *Eur J Immunol.* 2019;49(10):1457-1973.

De Biasi S, Paolini A, Lo Tartaro D, Gibellini L, Cossarizza A. Analysis of Antigen-Specific T and B Cells for Monitoring Immune Protection Against SARS-CoV-2. *Curr Protoc.* 2023 Jan;3(1):e636.

Ivison S, Malek M, Garcia RV, et al. A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. *JCI Insight.* 2018 Dec 6;3(23):e121867.

MORE DURAClone SOLUTIONS

DURAClone IF for Immune Functional Cytometry

The DURAClone IF panels reveal immune function at the single cell level utilizing a streamlined and simplified staining workflow.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm			
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	AF750
IF T Activation - B88649	25 tests - RUO	CD4	-	IFN γ	TNF α	-	-	IL-2	-	-	CD8	CD3
IF T Helper Cell - C04666	25 tests - RUO	IL-17A	-	IFN γ	-	-	-	IL-4	CD4	-	-	CD3
NEW IF NK Activation - D05474	25 tests - RUO	CD3/CD14	CD45	IFN γ				CD56			TNF α	
IF Monocytes Activation - C21858	25 tests - RUO	CD14	CD45	-	HLA-DR	-	-	-	-	-	TNF α	-
IF Basophil Activation - C23406	25 tests - RUO	CD63	CD45	-	CD203c	-	-	CD3	-	CD294 (CRTH2)	-	-

DURActive Stimulation Kits

The DURActive dry stimulation mixes ensure reliability of the first crucial step in cellular activation assays.

Product - Part Number	Size - Status	Contained Stimulating Agents	Matching DURAClone antibody panel
DURActive 1 - C11101	25 tests - RUO	PMA / Ionomycin / Brefeldin A	DURAClone IF T Activation; DURAClone IF T Helper Cell
DURActive 2 - C11102	25 tests - RUO	PMA / Ionomycin	Detection of soluble compounds, DURAClone IF T Activation, DURAClone IF T Helper Cell (using secretion inhibitors such as Monensin)
DURActive 3 - C21857	25 tests - RUO	LPS / Brefeldin A	DURAClone IF Monocyte Activation
NEW DURActive 4 - D05466	25 tests - RUO	IL-12 / IL-18 / Brefeldin A	DURAClone IF NK Activation

DURAClone RE for Rare Event Detection

The dry DURAClone RE panels enable sensitive detection of rare abnormal cell populations in blood or bone marrow using carefully optimized and highly dosed antibody combinations.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm		
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	APC-AF700	APC-AF750
RE CLB Tube - B80393	25 tests - RUO	CD20	CD45	CD81	ROR-1	-	CD79b	CD19	CD5	-	CD43
RE PC Tube - B80394	25 tests - RUO	CD38	CD45	CD81	CD27	-	CD19	CD200	CD138	-	CD56
RE ALB Tube - C00163	25 tests - RUO	-	CD45	CD58	-	CD34	CD10	CD19	-	CD38	CD20
RE CTC Tube* - C75112	15 tests - RUO	DAPI	-	Cytokeratin	-	-	-	CD45	CD326 (EpCAM)	-	-

*For use with PerFix CTC (C75118)

DURAClone SC for Human Adult Stem Cell Characterization

The DURAClone SC antibody panels enable rigorous human stem cell characterization in complex biological source materials as well as in enriched cellular products.

Product - Part Number	Size - Status	405 nm		488 nm					633 nm			
		PB	KrO	FITC	PE	ECD	PC5.5	PC7	APC	AF647	AF700	APC-AF750
SC Mesenchymal - C34369	25 tests - RUO	CD31	CD14/CD19	CD90	CD73	CD34	CD146	CD105	-	-	-	CD45
SC Hematopoietic - C49589	25 tests - RUO	CD90	CD45	CD38	CD49f	CD34	-	CD10	CD133	-	-	CD45RA

Choose Beckman Coulter for Benchmark Expertise and Innovation

For nearly 90 years Beckman Coulter has driven innovation. We remain committed to shaping flow cytometry technology to fit seamlessly into your lab's workflow and to provide an optimal user experience. When you choose a Beckman Coulter solution you receive a high level of expertise, innovation, and quality assurance.



Contact your sales representative



or visit <http://www.beckman.com/reagents/coulter-flow-cytometry/antibodies-and-kits/duraclone-panels>

PB: Pacific Blue[®]
KrO: Krome Orange
AF647: Alexa Fluor[®] 647

AF700: Alexa Fluor[®] 700
AF750: Alexa Fluor[®] 750
APC-AF700: APC-Alexa Fluor[®] 700

APC-AF750: APC-Alexa Fluor[®] 750

[®] Alexa Fluor and Pacific Blue are registered trademarks of Molecular Probes, Inc.



© 2024 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

For Beckman Coulter's worldwide office locations and phone numbers, please visit Contact Us at beckman.com

2023-GBL-EN-104547-v2

